Claritev Corp Stock Price, News & Analysis

Claritev Corporation (NYSE: CTEV) reported its Q1 2025 financial results with revenues of $231.3 million, representing a 1.4% decrease from Q1 2024. The company posted a net loss of $71.3 million, significantly improved from a $539.7 million loss in Q1 2024. Adjusted EBITDA reached $142.1 million with a 61.4% margin. Key developments include debt extension completion, rebranding to Claritev, and strategic partnerships with Oracle, J2 Health, and Burjeel Holdings. The company processed $42.9 billion in claim charges, identifying potential medical cost savings of $6.2 billion. Despite negative free cash flow of $(68.9) million, Claritev reaffirmed its full-year 2025 guidance, projecting revenue growth between -2% to flat and Adjusted EBITDA margin of 62.5-63.5%.

Claritev (NYSE: CTEV) has announced a strategic partnership with Lantern to enhance healthcare cost transparency and optimization. The collaboration integrates Claritev's BenInsights® and HST Connect® solutions with Lantern's Network of Excellence and TrueRate™ methodology. The partnership will focus on two key areas: Enhanced Data Analytics through BenInsights, providing comprehensive healthcare spending visibility, and Optimized Patient Steering via HST Connect, guiding patients to cost-effective, high-quality providers.

The partnership builds on previous joint research and aims to address surgical costs, which represent 20% of employer health spending. Through this collaboration, both companies aim to deliver meaningful savings for employer groups while improving patient care quality through data-driven surgical cost analysis.

Claritev Corporation (NYSE: CTEV) has appointed Jason Kap to its Board of Directors, effective immediately following his election at the Company's Annual Meeting on April 30, 2025. Kap brings over 20 years of leadership experience in technology, pricing, and product transformation strategies. He currently serves as CEO of Blue Rocket Incorporated and previously held leadership positions at Microsoft Corporation and Zipwire, Inc. The appointment aligns with Claritev's technology-driven transformation strategy in healthcare cost optimization and revenue integrity solutions.

As a visiting scholar at MIT (2013-2020) and with extensive board experience, Kap's expertise will support Claritev's mission to make healthcare more affordable, transparent, and fair through technology, data, and insights.

Claritev (NYSE: CTEV) and Claims Care Revenue Cycle Management, a Burjeel Holdings division, have signed a memorandum of understanding (MOU) to expand revenue cycle management solutions in the Middle East and North Africa region. The partnership aims to:

• Leverage Claritev's Payment and Revenue Integrity solutions for the MENA payer market
• Create a joint product roadmap for advanced revenue cycle management capabilities
• Combine Claritev's Advanced Code Editing and Decision Science with Claims Care's regional expertise
• Transition certain offshore business processes to Claims Care

The collaboration brings together US and MENA market leaders to promote affordable, transparent, and higher quality healthcare services, marking a significant step in Claritev's global expansion strategy.

Claritev (NYSE: CTEV) has announced two key appointments to strengthen its leadership team as part of its business transformation strategy. Dr. Jigar S. Patel will join as Chief Medical Officer effective April 14, 2025, bringing over 18 years of experience from Cerner/Oracle. He will provide medical guidance on strategic development and product innovation of Claritev's healthcare technology solutions.

Dr. Fernando Schwartz has been appointed as Chief Artificial Intelligence Officer, effective February 17, 2025. With 15 years of leadership in data science and machine learning, Schwartz previously served as VP of AI at ADP and led global data science strategy at Merck's Human Health Division. He will lead the company's AI and analytics strategy under Chief Digital Officer Michael Kim.

Claritev (NYSE: CTEV) announced that its data solution Ceres® has won the 'Data Solution of the Year for Insurance' award in the 6th annual Data Breakthrough Awards' Industry Applications Category. Ceres is designed to help supplemental carriers and benefits brokers provide unbiased benefit recommendations.

The platform leverages AI-powered insights and de-identified claims data from over a million members to transform supplemental plan design from an intuition-based process into a data-driven approach. The solution enables modeling of different census scenarios to determine which benefits provide the highest value through predicted utilization and payout amounts, benchmarked against similar employer groups.

According to Travis Dalton, Chairman, CEO and President of Claritev, Ceres exemplifies their philosophy that data and technology should empower rather than replace people. The platform aims to shift focus from lowest-cost offerings to high-value, population-specific plans.

Claritev (NYSE: CTEV) has scheduled its first quarter 2025 earnings conference call for Thursday, May 8, 2025, at 8:00 am Eastern Time. The company will release its Q1 2025 financial results the same day.

Participants can pre-register for the call through a provided link, after which they will receive a calendar invitation with access details and a unique PIN. A live webcast will be accessible through the company's Investor Relations website at investors.claritev.com/events-and-presentations, with participants advised to join ten minutes before the start time.

The earnings press release and supplemental slide deck will be available on the company website. For those unable to attend live, a replay will be available approximately two hours after the call through the archived webcast. Operator assistance is available at (404) 975-4839 or (833) 470-1428 with access code 685315.

Claritev (NYSE: CTEV), a healthcare technology company, has announced a sponsorship agreement with professional golfer Neal Shipley. As part of the deal, Shipley will display the Claritev logo on his shirt collar during competitions.

Shipley, 24, turned professional in summer 2024 following a notable amateur career where he made history as the low amateur at both the 2024 Masters Tournament and U.S. Open - becoming the ninth golfer in PGA TOUR history to achieve this distinction in the same year. He currently competes on the PGA TOUR Americas and has received sponsor exemptions for multiple PGA TOUR events.

The rising golf star was recently featured in the third season of Netflix's docuseries Full Swing, which captured his journey to the 2024 Masters and his experience playing alongside Tiger Woods in the final round.

ClearNote Health has announced a new agreement with Claritev (NYSE: CTEV) to make its Avantect® Pancreatic Cancer Test available through Claritev's national PHCS and MultiPlan Networks. The test is a DNA-based blood screening that combines epigenomic and genomic signals with machine learning to detect early pancreatic cancer indicators.

The Avantect test specifically targets high-risk patients, including:

• Type 2 diabetes patients aged 50 and older
• Individuals with relevant family history
• People with genetic predisposition

The test utilizes 5-hydroxymethylcytosine (5hmC) profiling in cell-free DNA and AI algorithms to detect tumor development earlier than conventional methods. This is particularly significant as pancreatic cancer often has only a 3% five-year survival rate when diagnosed at advanced stages.